Thomas Kleemann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Kleemann has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Margit Strauss
Klinikum Ludwigshafen, Medizinische Klinik B für Kardiologie, Pneumologie, Angiologie und Internistische Intensivmedizin, Ludwigshafen, Germany
12 shared publicationsRalf Zahn
Medizinische Klinik B, Klinikum Ludwigshafen, Ludwigshafen, Deutschland
10 shared publicationsKleopatra Kouraki
Klinikum Ludwigshafen, Medizinische Klinik B für Kardiologie, Pneumologie, Angiologie und Internistische Intensivmedizin, Ludwigshafen, Germany
8 shared publicationsKarlheinz Seidl
Medizinische Klinik I, Klinikum Ingolstadt, Ingolstadt, Germany
6 shared publicationsNicolas Werner
Klinikum Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany
4 shared publicationsSteffen Schneider
Institut für Herzinfarktforschung Ludwigshafen an der Universität Heidelberg
4 shared publications
Latest Publications
- 11 September 2025
- Published by Springer Nature in Herz
- Vol. 50 (6) , 446-452
Der erste ICD(implantierbarer Kardioverter-Defibrillator)-Schock
Zusammenfassung Patienten mit implantierbarem Kardioverter-Defibrillator (ICD), die einen adäquaten ICD-Schock erleiden, haben danach eine deutlich schlechtere Prognose. Trotz des Wissens um die Verschlechterung der Prognose gibt es in den Leitlinien keine klaren Handlungsanweisungen, wie nach dem Auftreten eines adäquaten ICD-Schocks zu verfahren ist. Das ToVAMI-Konzept stellt ein Behandlungsschema für Patienten mit erstem adäquaten ICD-Schock nach ventrikulären Tachykardien (VT) oder Kammerflimmern (VF) dar und besteht aus 3 Schritten: 1) To = Triggeroptimierung mit den folgenden Triggern, zusammengefasst unter dem Akronym ICD-STEMi (Ischämie/Compliance/Dekompensation/Stress/technische Ursache/Elektrolyt- bzw. endokrinologische Störung/Medikamentenintoxikation); 2) VA = ventrikuläre Arrhythmietherapie; 3) MI = medikamentöse und interventionelle prognostische Herzinsuffizienztherapie. Die Therapie nach dem ersten ICD-Schock besteht nicht nur aus Ablation oder antiarrhythmischer Therapie, sondern umfasst ein Paket diagnostischer und therapeutischer Maßnahmen, die ein systematisches Vorgehen erfordern. Die systematische Anwendung dieses Schemas kann die Detektionsrate an VT/VF auslösenden Triggerfaktoren erhöhen und wesentlich zu einer optimierten medikamentösen und interventionellen prognostischen Herzinsuffizienzbehandlung beitragen. Etwa 10 % der Patienten zeigen im Rahmen des Auftretens des ersten ICD-Schocks trotz objektiver Hinweise auf eine fortschreitende Herzinsuffizienz oder Ischämie keine klinischen Symptome einer sich verschlechternden Herzinsuffizienz oder Ischämie. Bei diesen Patienten ist der erste VT/VF-Schock das einzige Warnsignal für eine Verschlechterung der kardialen Situation. Dies unterstreicht die Notwendigkeit einer systematischen Diagnostik und Therapie nach dem ersten ICD-Schock.
- 11 September 2025
- Published by Springer Nature in Herz
- Vol. 50 (6) , 446-452
Der erste ICD(implantierbarer Kardioverter-Defibrillator)-Schock
Zusammenfassung Patienten mit implantierbarem Kardioverter-Defibrillator (ICD), die einen adäquaten ICD-Schock erleiden, haben danach eine deutlich schlechtere Prognose. Trotz des Wissens um die Verschlechterung der Prognose gibt es in den Leitlinien keine klaren Handlungsanweisungen, wie nach dem Auftreten eines adäquaten ICD-Schocks zu verfahren ist. Das ToVAMI-Konzept stellt ein Behandlungsschema für Patienten mit erstem adäquaten ICD-Schock nach ventrikulären Tachykardien (VT) oder Kammerflimmern (VF) dar und besteht aus 3 Schritten: 1) To = Triggeroptimierung mit den folgenden Triggern, zusammengefasst unter dem Akronym ICD-STEMi (Ischämie/Compliance/Dekompensation/Stress/technische Ursache/Elektrolyt- bzw. endokrinologische Störung/Medikamentenintoxikation); 2) VA = ventrikuläre Arrhythmietherapie; 3) MI = medikamentöse und interventionelle prognostische Herzinsuffizienztherapie. Die Therapie nach dem ersten ICD-Schock besteht nicht nur aus Ablation oder antiarrhythmischer Therapie, sondern umfasst ein Paket diagnostischer und therapeutischer Maßnahmen, die ein systematisches Vorgehen erfordern. Die systematische Anwendung dieses Schemas kann die Detektionsrate an VT/VF auslösenden Triggerfaktoren erhöhen und wesentlich zu einer optimierten medikamentösen und interventionellen prognostischen Herzinsuffizienzbehandlung beitragen. Etwa 10 % der Patienten zeigen im Rahmen des Auftretens des ersten ICD-Schocks trotz objektiver Hinweise auf eine fortschreitende Herzinsuffizienz oder Ischämie keine klinischen Symptome einer sich verschlechternden Herzinsuffizienz oder Ischämie. Bei diesen Patienten ist der erste VT/VF-Schock das einzige Warnsignal für eine Verschlechterung der kardialen Situation. Dies unterstreicht die Notwendigkeit einer systematischen Diagnostik und Therapie nach dem ersten ICD-Schock.
- Open Access
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Efficacy of a gentamycin-collagen sponge to prevent infection in implantable cardioverter defibrillator patients undergoing revision surgery - results of a monocentric ICD registry observational study
Introduction: Despite the obvious benefits, the use of implantable cardioverter defibrillators (ICDs) is associated with serious complications, including infections. In particular, device replacement or revision procedures are associated with an increased risk of infection. Aim of the study was to compare the cardiac device infection rate with and without the use of the gentamycin-collagen sponge (GCS) in patients undergoing device replacement or revision procedures of implanted ICDs. Methods: A total of 491 consecutive ICD patients from a prospective single-centre ICD-registry who underwent elective device replacement, system upgrade or lead revision between 2017 and 6/2023 were analyzed. From September 2020 onwards, a GCS was inserted into the device pocket (GCS group, n = 256). These patients were compared to the patients implanted/ revised between 2017 and 8/2020 (control group, n = 235). Results: The baseline characteristics and the PADIT score were similar in both groups (Table 1). The GCS was well tolerated and there were no complications associated with the GCS. The mean follow-time was 15 + 10 months in the GCS group and 30 + 11 months in the control group. The Kaplan-Meier estimated infection rate after one year was 1.0% in the GCS group and 3.5% in the control group (p = 0.03, Figure 1). Time from revision to infection was 144 + 134 days in the GCS group vs. 362 + 297 days in the control group. Conclusion: Adjunctive use of a GCS was associated with a lower incidence of device infections than standard-of-care infection-prevention strategies alone.
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Open AccessEfficacy of a gentamycin-collagen sponge to prevent infection in implantable cardioverter defibrillator patients undergoing revision surgery - results of a monocentric ICD registry observational study
Introduction: Despite the obvious benefits, the use of implantable cardioverter defibrillators (ICDs) is associated with serious complications, including infections. In particular, device replacement or revision procedures are associated with an increased risk of infection. Aim of the study was to compare the cardiac device infection rate with and without the use of the gentamycin-collagen sponge (GCS) in patients undergoing device replacement or revision procedures of implanted ICDs. Methods: A total of 491 consecutive ICD patients from a prospective single-centre ICD-registry who underwent elective device replacement, system upgrade or lead revision between 2017 and 6/2023 were analyzed. From September 2020 onwards, a GCS was inserted into the device pocket (GCS group, n = 256). These patients were compared to the patients implanted/ revised between 2017 and 8/2020 (control group, n = 235). Results: The baseline characteristics and the PADIT score were similar in both groups (Table 1). The GCS was well tolerated and there were no complications associated with the GCS. The mean follow-time was 15 + 10 months in the GCS group and 30 + 11 months in the control group. The Kaplan-Meier estimated infection rate after one year was 1.0% in the GCS group and 3.5% in the control group (p = 0.03, Figure 1). Time from revision to infection was 144 + 134 days in the GCS group vs. 362 + 297 days in the control group. Conclusion: Adjunctive use of a GCS was associated with a lower incidence of device infections than standard-of-care infection-prevention strategies alone.
- 16 April 2023
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (5) , 1241-1248
The role of trigger factors in the occurrence of appropriate ICD shocks and their clinical and prognostic implications
Background: The role of triggers in the occurrence of appropriate implantable cardioverter‐defibrillator (ICD) shocks due to ventricular tachyarrhythmias is not well known. The aim of the study was to assess the prevalence of trigger factors in appropriate ICD shocks and to analyze their prognostic impact on clinical outcome.Methods: A total of 710 consecutive patients of a prospective single‐center ICD‐registry who received a first appropriate ICD shock between 2000 and 9/2021 were analyzed.Results: In 35% of ICD patients with first ICD shock, at least one of the following triggers was found: Ischemia (22%), Compliance (9%), Decompensation (38%), Stress (12%), Technical (5%), Electrolyte/endocrinological disorder (22%) and Medication side effects (4%). The trigger factors can be summarized under the acronym ICD‐STEMi. The prospective application of the ICD‐STEMi scheme increased the rate of identified triggers from 32% to 56% (p < .001). Patients with triggered first ICD shock had an increased 5‐year mortality rate (50% vs. 38%, p < .001). Patients with triggers did not show different mortality outcomes or recurrent ICD shocks whether they received arrhythmia therapy or not.Conclusions: The evaluation of trigger factors after the occurrence of ICD shocks is mandatory and can be systematically evaluated using the acronym ICD‐STEMi. Systematic evaluation of triggers using the ICD‐STEMi scheme can identify triggers in about half of ICD patients with first appropriate ICD shock. Patients with triggered ICD shock have a 12% higher 5‐year mortality rate.
- 16 April 2023
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (5) , 1241-1248
The role of trigger factors in the occurrence of appropriate ICD shocks and their clinical and prognostic implications
Background: The role of triggers in the occurrence of appropriate implantable cardioverter‐defibrillator (ICD) shocks due to ventricular tachyarrhythmias is not well known. The aim of the study was to assess the prevalence of trigger factors in appropriate ICD shocks and to analyze their prognostic impact on clinical outcome.Methods: A total of 710 consecutive patients of a prospective single‐center ICD‐registry who received a first appropriate ICD shock between 2000 and 9/2021 were analyzed.Results: In 35% of ICD patients with first ICD shock, at least one of the following triggers was found: Ischemia (22%), Compliance (9%), Decompensation (38%), Stress (12%), Technical (5%), Electrolyte/endocrinological disorder (22%) and Medication side effects (4%). The trigger factors can be summarized under the acronym ICD‐STEMi. The prospective application of the ICD‐STEMi scheme increased the rate of identified triggers from 32% to 56% (p < .001). Patients with triggered first ICD shock had an increased 5‐year mortality rate (50% vs. 38%, p < .001). Patients with triggers did not show different mortality outcomes or recurrent ICD shocks whether they received arrhythmia therapy or not.Conclusions: The evaluation of trigger factors after the occurrence of ICD shocks is mandatory and can be systematically evaluated using the acronym ICD‐STEMi. Systematic evaluation of triggers using the ICD‐STEMi scheme can identify triggers in about half of ICD patients with first appropriate ICD shock. Patients with triggered ICD shock have a 12% higher 5‐year mortality rate.
- 24 January 2023
- Published by Springer Nature in Herz
- Vol. 48 (1) , 72-86
Supraventricular tachycardia
Supraventricular tachycardia is a common occurrence in routine clinical practice. As a physician, one can encounter them everywhere, whether as a general practitioner or as an emergency doctor in a hospital. Some tachycardias might have robbed an on-call doctor the night or the last nerve; however, supraventricular tachycardia is usually a benign condition that is easily treatable and, in many cases, even curable. This article covers the differential diagnoses of supraventricular tachycardia and its treatment options. Atrial fibrillation, also a supraventricular tachycardia, is not discussed in this article.
- 24 January 2023
- Published by Springer Nature in Herz
- Vol. 48 (1) , 72-86
Supraventricular tachycardia
Supraventricular tachycardia is a common occurrence in routine clinical practice. As a physician, one can encounter them everywhere, whether as a general practitioner or as an emergency doctor in a hospital. Some tachycardias might have robbed an on-call doctor the night or the last nerve; however, supraventricular tachycardia is usually a benign condition that is easily treatable and, in many cases, even curable. This article covers the differential diagnoses of supraventricular tachycardia and its treatment options. Atrial fibrillation, also a supraventricular tachycardia, is not discussed in this article.
- Open Access
- 2 September 2021
- Published by Elsevier in Heart Rhythm O2
- Vol. 2 (5) , 537-540
Management of implantable cardioverter-defibrillator patients with appropriate ICD shocks: A 3-step treatment concept
- 2 September 2021
- Published by Elsevier in Heart Rhythm O2
- Vol. 2 (5) , 537-540
Open AccessManagement of implantable cardioverter-defibrillator patients with appropriate ICD shocks: A 3-step treatment concept
- 24 April 2020
- Published by Georg Thieme Verlag KG in Notaufnahme up2date
- Vol. 2 (02) , 143-156
Akute Notfälle bei Schrittmacher- und ICD-Trägern
In der Zentralen Notaufnahme (ZNA) präsentieren sich immer mehr Patienten mit Schrittmacher oder implantierbarem Kardioverter-Defibrillator (ICD). Diese Geräte können in ihrer Funktion versagen, Komplikationen mit sich bringen oder Alarmsignale abgeben, die den beunruhigten Patienten in die ZNA führen. Dieser Beitrag soll akute Notfälle bei Schrittmacher- oder ICD-Trägern zusammenfassen, mit denen ein Aufnahmearzt in der ZNA konfrontiert werden kann.
- 24 April 2020
- Published by Georg Thieme Verlag KG in Notaufnahme up2date
- Vol. 2 (02) , 143-156
Akute Notfälle bei Schrittmacher- und ICD-Trägern
In der Zentralen Notaufnahme (ZNA) präsentieren sich immer mehr Patienten mit Schrittmacher oder implantierbarem Kardioverter-Defibrillator (ICD). Diese Geräte können in ihrer Funktion versagen, Komplikationen mit sich bringen oder Alarmsignale abgeben, die den beunruhigten Patienten in die ZNA führen. Dieser Beitrag soll akute Notfälle bei Schrittmacher- oder ICD-Trägern zusammenfassen, mit denen ein Aufnahmearzt in der ZNA konfrontiert werden kann.
- 22 July 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (10) , 2012-2019
Long‐term performance and lead failure analysis of the Durata defibrillation lead compared to its previous model, the recalled Riata defibrillation lead
Introduction: Data on long‐term durability of St Jude Medical Durata defibrillation leads compared to its previous model, the St Jude Medical Riata leads in clinical practice are missing. Aim of the study was to analyze the long‐term performance of the Durata defibrillation leads compared to the Riata leads in clinical practice.Methods and Results: A total of 1407 consecutive patients of a prospective single‐centre implantable cardioverter defibrillator (ICD)‐registry were analyzed who underwent ICD implantation with a Durata (n = 913) or Riata (n = 494) ICD lead between 2002 and 2017. Most of the leads were implanted via a subclavian vein access. The estimated lead defect rates after 5 and 10 years were not different between the Durata (11% and 36%) and Riata leads (13% and 38%). Among Durata leads single coil and DF‐4 connector ICD leads had a lower incidence of lead failure. Major causes of lead failure were compression of the lead in the clavicular region, generator to lead friction and distal fatigue fracture whereas lead defect due to externalization was a rare cause of lead defect in Riata leads (3%).Conclusion: Among ICD leads implanted via the subclavian vein access the lead defect rate of Durata leads after 10 years is similar to that of Riata leads. Single coil and DF‐4 ICD leads are associated with a lower lead failure rate. Mechanical stress represents a major cause of lead failure mechanism whereas externalization might only play a minor role in clinical practice.
- 22 July 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (10) , 2012-2019
Long‐term performance and lead failure analysis of the Durata defibrillation lead compared to its previous model, the recalled Riata defibrillation lead
Introduction: Data on long‐term durability of St Jude Medical Durata defibrillation leads compared to its previous model, the St Jude Medical Riata leads in clinical practice are missing. Aim of the study was to analyze the long‐term performance of the Durata defibrillation leads compared to the Riata leads in clinical practice.Methods and Results: A total of 1407 consecutive patients of a prospective single‐centre implantable cardioverter defibrillator (ICD)‐registry were analyzed who underwent ICD implantation with a Durata (n = 913) or Riata (n = 494) ICD lead between 2002 and 2017. Most of the leads were implanted via a subclavian vein access. The estimated lead defect rates after 5 and 10 years were not different between the Durata (11% and 36%) and Riata leads (13% and 38%). Among Durata leads single coil and DF‐4 connector ICD leads had a lower incidence of lead failure. Major causes of lead failure were compression of the lead in the clavicular region, generator to lead friction and distal fatigue fracture whereas lead defect due to externalization was a rare cause of lead defect in Riata leads (3%).Conclusion: Among ICD leads implanted via the subclavian vein access the lead defect rate of Durata leads after 10 years is similar to that of Riata leads. Single coil and DF‐4 ICD leads are associated with a lower lead failure rate. Mechanical stress represents a major cause of lead failure mechanism whereas externalization might only play a minor role in clinical practice.
- Open Access
- 17 July 2019
- Published by Wiley in Clinical Cardiology
- Vol. 42 (10) , 866-872
Contemporary benefit‐harm profile over two decades in primary prophylactic ICD‐therapy
Background: Implantable cardioverter defibrillator (ICD) was implemented into clinical routine more than 20 years ago. Since then, ICD therapy became standard therapy for primary and secondary prevention of sudden cardiac death in clinical practice.Objectives: Aim of the study was to evaluate the benefit‐harm profile of contemporary primary prophylactic ICD therapy.Methods: A total of 1222 consecutive patients of a prospective single‐center ICD‐registry were analyzed who underwent primary prophylactic ICD implantation between 2000 and 2017. Patients were divided into two groups according to the implantation year: 2010‐2017 (group 1, n = 579) and 2000‐2009 (group 2, n = 643).Results: The rate of estimated appropriate ICD therapy after 8 years was 51% in the 2000s and 42% in the 2010s (P < .001). The complication rate changed slightly from 53% to 47% (P = .005). This decline was mainly driven by the reduction of inappropriate ICD shocks (30% vs 14%, P < .001) whereas the rate of ICD shock lead malfunction and device/ lead infection remained unchanged over time. Nonischemic cardiomyopathy was an independent predictor for ICD complications without benefit of ICD therapy (HR 1.37, 95% CI 1.07‐1.77).Conclusion: The ICD therapy rate for ventricular arrhythmias in patients with primary prophylactic ICD implantation is decreasing over the last two decades. Complication rate remains high due to an unchanged rate of ICD shock malfunctions and device infections. Nonischemic cardiomyopathy is an independent predictor for ICD complications without benefit of ICD therapy in primary prophylactic ICD‐therapy.
- 17 July 2019
- Published by Wiley in Clinical Cardiology
- Vol. 42 (10) , 866-872
Open AccessContemporary benefit‐harm profile over two decades in primary prophylactic ICD‐therapy
Background: Implantable cardioverter defibrillator (ICD) was implemented into clinical routine more than 20 years ago. Since then, ICD therapy became standard therapy for primary and secondary prevention of sudden cardiac death in clinical practice.Objectives: Aim of the study was to evaluate the benefit‐harm profile of contemporary primary prophylactic ICD therapy.Methods: A total of 1222 consecutive patients of a prospective single‐center ICD‐registry were analyzed who underwent primary prophylactic ICD implantation between 2000 and 2017. Patients were divided into two groups according to the implantation year: 2010‐2017 (group 1, n = 579) and 2000‐2009 (group 2, n = 643).Results: The rate of estimated appropriate ICD therapy after 8 years was 51% in the 2000s and 42% in the 2010s (P < .001). The complication rate changed slightly from 53% to 47% (P = .005). This decline was mainly driven by the reduction of inappropriate ICD shocks (30% vs 14%, P < .001) whereas the rate of ICD shock lead malfunction and device/ lead infection remained unchanged over time. Nonischemic cardiomyopathy was an independent predictor for ICD complications without benefit of ICD therapy (HR 1.37, 95% CI 1.07‐1.77).Conclusion: The ICD therapy rate for ventricular arrhythmias in patients with primary prophylactic ICD implantation is decreasing over the last two decades. Complication rate remains high due to an unchanged rate of ICD shock malfunctions and device infections. Nonischemic cardiomyopathy is an independent predictor for ICD complications without benefit of ICD therapy in primary prophylactic ICD‐therapy.
- 13 May 2019
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 109 (1) , 89-95
Prognostic relevance of new onset arrhythmia and ICD shocks in primary prophylactic ICD patients
The prognostic relevance of new onset arrhythmias compared to ICD shocks in ICD patients is not well known.
- 13 May 2019
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 109 (1) , 89-95
Prognostic relevance of new onset arrhythmia and ICD shocks in primary prophylactic ICD patients
The prognostic relevance of new onset arrhythmias compared to ICD shocks in ICD patients is not well known.